The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy.

ABSTRACT:

Background/aims

Before tenofovir (TDF) become available in South Korea, combination therapy with entecavir (ETV) and adefovir (ADV) was the most potent regimen for chronic hepatitis B (CHB) patients who fail to respond to rescue therapy for drug resistance. We analyzed the efficacy of ETV-ADV combination therapy and investigated the clinical and clonal results of TDF-based rescue therapy in CHB patients refractory to this combination.

Methods

We retrospectively reviewed the medical records of CHB patients treated for up to 3 years with ETV-ADV combination therapy as a rescue therapy for drug resistance. In cases refractory to this combination, clinical and clonal analyses were performed for TDF-based rescue therapy.

Results

The analysis was performed on 48 patients. T

SUBMITTER: Kim JH 

PROVIDER: S-EPMC4946405 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature